Cargando…

Gemcitabine Therapy in Patients with Advanced Pancreatic Cancer

BACKGROUND: Advanced, unresectable pancreatic cancer is an extremely aggressive disease. The 5-year survival rate for pancreatic cancer is only less than 5%. Current therapeutic options for patients with locally advanced or metastatic disease are limited. This analysis is a retrospective evaluation...

Descripción completa

Detalles Bibliográficos
Autores principales:	Min, Young Joo, Joo, Kwang Ro, Park, Neung Hwa, Yun, Tae Kwon, Nah, Yang Won, Nam, Chang Woo, Park, Jae Hoo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Association of Internal Medicine 2002
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4531686/ https://www.ncbi.nlm.nih.gov/pubmed/12647642 http://dx.doi.org/10.3904/kjim.2002.17.4.259

Ejemplares similares

A Case of Chronic Pancreatitis Associated with Liver Infarction and Acrodermatitis Enteropathica
por: Kim, Byung Chul, et al.
Publicado: (2002)

The role of bile carcinoembryonic antigen in diagnosing bile duct cancer.
por: Joo, Kwang Ro, et al.
Publicado: (2003)

A Case of Simultaneous Xanthogranulomatous Cholecystitis and Carcinoma of the Gallbladder
por: Lee, Hyo Sup, et al.
Publicado: (2003)

Induction Chemotherapy with Gemcitabine and Cisplatin Followed by Simultaneous Integrated Boost–Intensity Modulated Radiotherapy with Concurrent Gemcitabine for Locally Advanced Unresectable Pancreatic Cancer: Results from a Feasibility Study
por: Woo, Sang Myung, et al.
Publicado: (2017)

A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-line chemotherapy for advanced pancreatic cancer in South Korea
por: Lee, Hee Seung, et al.
Publicado: (2017)

Duodenal Duplicated Cyst Manifested by Acute Pancreatitis and Obstructive Jaundice in an Elderly Man
por: Jo, Young Chul, et al.
Publicado: (2004)

A phase II study of gemcitabine, erlotinib and S-1 in patients with advanced pancreatic cancer
por: Han, Boram, et al.
Publicado: (2021)

The anti-fibrotic effect of GV1001 combined with gemcitabine on treatment of pancreatic ductal adenocarcinoma
por: Park, Joo Kyung, et al.
Publicado: (2016)

Concomitant Statin Use Has a Favorable Effect on Gemcitabine-Erlotinib Combination Chemotherapy for Advanced Pancreatic Cancer
por: Moon, Do Chang, et al.
Publicado: (2016)

Gemcitabine and Erlotinib with or without Oxaliplatin in Previously Untreated Advanced Pancreatic Cancer: A Randomized Phase II Trial
por: Lim, Sung Hee, et al.
Publicado: (2021)

Phase II Trial of Erlotinib Plus Gemcitabine Chemotherapy in Korean Patients with Advanced Pancreatic Cancer and Prognostic Factors for Chemotherapeutic Response
por: Park, Semi, et al.
Publicado: (2013)

Analysis of Clinical Predictive Factors Affecting the Outcome of Second-Line Chemotherapy for Gemcitabine-Refractory Advanced Pancreatic Cancer
por: Lee, Jeung Eun, et al.
Publicado: (2020)

Gemcitabine Combined with Capecitabine Compared to Gemcitabine with or without Erlotinib as First-Line Chemotherapy in Patients with Advanced Pancreatic Cancer
por: Lim, Jae Yun, et al.
Publicado: (2015)

Gastrointestinal Hemorrhage after Concurrent Chemoradiotherapy in Locally Advanced Pancreatic Cancer
por: Lee, Kyong Joo, et al.
Publicado: (2013)

Oral chemotherapy for second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer
por: Park, Se Jun, et al.
Publicado: (2019)

Comparison of capecitabine and 5-fluorouracil in chemoradiotherapy for locally advanced pancreatic cancer
por: Kim, Yeon-Joo, et al.
Publicado: (2013)

α, γ-Mangostins Induce Autophagy and Show Synergistic Effect with Gemcitabine in Pancreatic Cancer Cell Lines
por: Kim, Myoungjae, et al.
Publicado: (2017)

Efficacy of Capecitabine Plus Oxaliplatin Combination Chemotherapy for Advanced Pancreatic Cancer after Failure of First-Line Gemcitabine-Based Therapy
por: Chung, Kwang Hyun, et al.
Publicado: (2017)

Gemcitabine-Induced Hemolytic Uremic Syndrome in Pancreatic Cancer: A Case Report and Review of the Literature
por: Lee, Hye Won, et al.
Publicado: (2014)

Pancreatitis from Metastatic Small Cell Lung Cancer: Successful Treatment with Endoscopic Intrapancreatic Stenting
por: Woo, Jong-Shin, et al.
Publicado: (2006)

A phase I/II study of ivaltinostat combined with gemcitabine and erlotinib in patients with untreated locally advanced or metastatic pancreatic adenocarcinoma
por: Jo, Jung Hyun, et al.
Publicado: (2022)

Erlotinib plus gemcitabine versus gemcitabine for pancreatic cancer: real-world analysis of Korean national database
por: Shin, Sangjin, et al.
Publicado: (2016)

Comparison between FOLFIRINOX and gemcitabine plus nab-paclitaxel including sequential treatment for metastatic pancreatic cancer: a propensity score matching approach
por: Chun, Jung Won, et al.
Publicado: (2021)

Real-world outcomes of adjuvant gemcitabine versus gemcitabine plus capecitabine for resected pancreatic ductal adenocarcinoma
por: Kang, Sora, et al.
Publicado: (2022)

Current trends in the management of pancreatic cystic neoplasms in Korea: a national survey
por: Chon, Hyung Ku, et al.
Publicado: (2022)

Phase II Trial of Postoperative Adjuvant Gemcitabine and Cisplatin Chemotherapy Followed by Chemoradiotherapy with Gemcitabine in Patients with Resected Pancreatic Cancer
por: Lee, Kyung-Hun, et al.
Publicado: (2021)

Combinatorial immunotherapy with gemcitabine and ex vivo-expanded NK cells induces anti-tumor effects in pancreatic cancer
por: Koh, Eun-Kyoung, et al.
Publicado: (2023)

Novel Strategy with Gemcitabine for Advanced Pancreatic Cancer
por: Komori, Shuji, et al.
Publicado: (2011)

A novel HDAC inhibitor, CG200745, inhibits pancreatic cancer cell growth and overcomes gemcitabine resistance
por: Lee, Hee Seung, et al.
Publicado: (2017)

A Phase II Trial of Gemcitabine plus Capecitabine for Patients with Advanced Pancreatic Cancer
por: Choi, Jong Gwon, et al.
Publicado: (2012)

Comparison between three types of needles for endoscopic ultrasound-guided tissue acquisition of pancreatic solid masses: a multicenter observational study
por: Yang, Min Jae, et al.
Publicado: (2023)

Neoadjuvant chemoradiation with Gemcitabine for locally advanced pancreatic cancer
por: Habermehl, Daniel, et al.
Publicado: (2012)

Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study
por: Demols, A, et al.
Publicado: (2006)

Gemcitabine plus concurrent irreversible electroporation vs gemcitabine alone for locally advanced pancreatic cancer
por: Ma, Yang-Yang, et al.
Publicado: (2020)

Attenuated FOLFIRINOX in the salvage treatment of gemcitabine-refractory advanced pancreatic cancer: a phase II study
por: Kim, Jung Hoon, et al.
Publicado: (2018)

FOLFIRINOX vs gemcitabine/nab-paclitaxel for treatment of metastatic pancreatic cancer: Single-center cohort study
por: Cho, In Rae, et al.
Publicado: (2020)

A Multicenter Phase II Trial of Gemcitabine Plus Oxaliplatin in Unresectable Gallbladder Cancer
por: Woo, Sang Myung, et al.
Publicado: (2013)

Incidence, mortality and survival of gallbladder, extrahepatic bile duct, and pancreatic cancer using Korea central cancer registry database: 1999-2019
por: Kang, Mee Joo, et al.
Publicado: (2022)

Current Practice Patterns of Endoscopic Ultrasound-Guided Tissue Sampling for Pancreatic Solid Mass in Korea: Outcomes of a National Survey
por: Ahn, Dong-Won, et al.
Publicado: (2023)

Alterations in Pharmacokinetics of Gemcitabine and Erlotinib by Concurrent Administration of Hyangsayukgunja-Tang, a Gastroprotective Herbal Medicine
por: Kim, Tae Hwan, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_tjp1q8195qm7ao89u3drjjkp39